StockData
Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc. (SANA) stock

SANANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$1.85−0.03 (-1.60%)

Close on Nov 18, 2026Market cap $553.82MP/E –Yield –

Earnings

Sana Biotechnology's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 2, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
–
Non-GAAP net loss per share, Q3 FY2026
-$0.14
Latest guidance
Reaffirmed
Aug 8, 2024 · 1 item

Quarterly results

Revenue and earnings per share from each of Sana Biotechnology's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Mar 2, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close––$0.07-$0.14Release
Q2 FY2026ended Jun 30, 2026Aug 10, 2026after the close––––Release
Q1 FY2026ended Mar 31, 2026May 11, 2026after the close––-$0.17-$0.14Release
Q4 FY2025ended Dec 31, 2025Mar 3, 2026after the close––-$0.21-$0.16Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025after the close––––Release
Q2 FY2025ended Jun 30, 2025Aug 11, 2025after the close––$0.39$0.16Release
Q1 FY2025ended Mar 31, 2025May 8, 2025after the close––$0.21$0.20Release
Q4 FY2024ended Dec 31, 2024Mar 17, 2025after the close––-$0.21-$0.23Release
Q3 FY2024ended Sep 30, 2024Nov 8, 2024before the open––-$0.25-$0.27Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024after the close––-$0.21-$0.32Release
Q1 FY2024ended Mar 31, 2024May 8, 2024after the close––$0.49$0.32Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Sana Biotechnology guided for has been reported

Guidance history

Every forecast Sana Biotechnology put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 8, 2024operating cash burnFY2024$200.00MReaffirmed
Feb 29, 2024patients treatedFY202440 – 60New
Feb 29, 2024operating cash burnFY2024$200.00MReaffirmed
Nov 8, 2023operating cash burnFY2024$200.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Sana Biotechnology filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Results
  4. Results
  5. Results
  6. Update
  7. Update
  8. Results
  9. Results
  10. News
  11. News
  12. Results
  13. Results
  14. Update
  15. Results

See a number that looks wrong?